BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1413 related articles for article (PubMed ID: 8949573)

  • 1. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
    Van den Berghe G; Wouters P; Bowers CY; de Zegher F; Bouillon R; Veldhuis JD
    Eur J Endocrinol; 1999 Jan; 140(1):17-22. PubMed ID: 10037246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
    Van den Berghe G; de Zegher F; Baxter RC; Veldhuis JD; Wouters P; Schetz M; Verwaest C; Van der Vorst E; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Feb; 83(2):309-19. PubMed ID: 9467533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
    Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Iranmanesh A; Veldhuis JD; Bouillon R
    Clin Endocrinol (Oxf); 2002 May; 56(5):655-69. PubMed ID: 12030918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.
    Bowers CY; Reynolds GA; Durham D; Barrera CM; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1990 Apr; 70(4):975-82. PubMed ID: 2108187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
    Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone.
    De Marinis L; Mancini A; Valle D; Bianchi A; Gentilella R; Liberale I; Mignani V; Pennisi M; Della Corte F
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):741-7. PubMed ID: 10468946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyrotropin-releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations.
    Van den Berghe G; de Zegher F; Vlasselaers D; Schetz M; Verwaest C; Ferdinande P; Lauwers P
    Crit Care Med; 1996 Apr; 24(4):590-5. PubMed ID: 8612408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.
    Van den Berghe G; Wouters P; Weekers F; Mohan S; Baxter RC; Veldhuis JD; Bowers CY; Bouillon R
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1311-23. PubMed ID: 10199772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly.
    Hanew K; Utsumi A; Sugawara A; Shimizu Y; Abe K
    J Clin Endocrinol Metab; 1994 Mar; 78(3):509-12. PubMed ID: 8126120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
    Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.
    Pimentel-Filho FR; Ramos-Dias JC; Ninno FB; Façanha CF; Liberman B; Lengyel AM
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):295-300. PubMed ID: 9156038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion.
    Alba-Roth J; Müller OA; Schopohl J; von Werder K
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1186-9. PubMed ID: 2903866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.